Condition
Overweight
Obesity
Locations
China
Start date
11/08/2025
Identifiers
Trial ID NN9490-8213,
NCT number NCT07121153,
Eudract number Not Available
NCT number NCT07121153,
Eudract number Not Available
Summary
The study is testing a new medicine (NNC0487-0111) for weight control in Chinese people with BMI between 24 kilogram per meter square (kg/m2) and 34.9 kg/m2. The aim of the study is to see how safe the study medicine is and how it behaves in human body. Participants will either get the study medicine or placebo (a "dummy medicine" similar to the study medicine but without active ingredients) and which treatment they get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors but has previously been tested in humans. This study will last for up to 53 days.
Trial Overview:
Treatment
DRUG: NNC0487-0111 A
DRUG: Placebo A
Study type
INTERVENTIONAL
Trial duration
Aug 11 2025 - Jan 11 2026
Participants
36
Phase
I
Are you eligible?
Gender
MALE
Age
18 to 55 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.